May 2002
Bacteria - not parasitic worms - play a critical role in causing river blindness
Researchers of infectious ophthalmological disease have finally succeeded in pinpointing the true causative agent of river blindness - a bacterium known as Wolbachia. The highly celebrated research finding may lead to a variety of new strategies for treating the disease.
Read More.

April 2002
Eyes aren't just for vision anymore…
Researchers at the Howard Hughes Medical Institute and Johns Hopkins Medical School in the United States have recently reported a mechanism through which the body might control its internal clock.
Read More.

February 2002
Digital analysis ignites explosion of data on retinal health and disease
The latest techniques of molecular biology are providing researchers with a veritable “Garden of Eden” of research opportunities into the health and disease of photoreceptor neurons in the retina.
Read More.

January 2002
Eyes in the back of your head: And other strange tales from the coal face of molecular research Microchips may one day “see” for persons with severe macular degeneration, a leading scientist has forecast.
Read More.

December 2001
French biotechnology companies focus on drug delivery to the eye.
A French company, Neurotech, established in 1995 by leading French and US neuroscientists are promising to make significant advances in the field of central nervous system and ophthalmic protein/cell therapy.
Read More.

October 2001
French biotechnology companies focus on drug delivery to the eye
A French company, Neurotech, established in 1995 by leading French and US neuroscientists are promising to make significant advances in the field of central nervous system and ophthalmic protein/cell therapy.
Read More.

September 2001
French biotechnology companies focus on drug delivery to the eye
A French company, Neurotech, established in 1995 by leading French and US neuroscientists are promising to make significant advances in the field of central nervous system and ophthalmic protein/cell therapy.
Read More.

July 2001
Novel Recombinant Drug Suppresses the Rejection of Allogeneic Corneal Transplants
A research team at the Department of Ophthalmology, Harvard Medical School -using a drug produced by recombinant DNA techniques-- has successfully demonstrated a significant reduction in the incidence of allogeneic corneal transplant rejection in laboratory animals.
Read More.

May 2001
First Steps Towards A Gene-Based Approach For Attacking CMV Retinitis
Researchers from the National Eye Institute, Bethesda, Maryland have recently reported the successful inhibition of cytomegalovirus infection in human retinal pigment epithelium cells. A genetic drug, ISIS 2922, designed using information from the genetic sequence of the cytomegalovirus genome, is the first drug of its type to be approved for use by the US FDA.
Read More.

Top